Research progress of autophagy in esophageal cancer

doi:10.3877/cma.j.issn.2095-8773.2016.01.046

Abstract

Abstract:

Autophagy is one of the biological processes that under the influence of various external factors, eukaryotic cells degrade damaged organelles, unfolded proteins and intracellular pathogens to lysosomes as well as provide the cells with nutrients and energy which can re-engage life activities. Autophagy plays an important role in maintaining homeostasis and so on. At present, the incidence and mortality rates of esophageal cancer in China are much higher than the world average. The radiotherapy and chemotherapy combined with targeted therapy have gradually gained wide application in the treatment of esophageal cancer, and these novel therapeutic measures are related to cell autophagy. The regulatory mechanism of autophagy in the development of esophageal cancer is introduced in this paper.

Key words: Autophagy, Esophageal cancer, Beclin1

Qianqian Cao, Yu Liu, Wenhui Li, Yusheng Shu. Research progress of autophagy in esophageal cancer[J]. Chinese Journal of Thoracic Surgery(Electronic Edition), 2016, 03(01): 46-50.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhxbwkdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-8773.2016.01.046

https://zhxbwkdzzz.cma-cmc.com.cn/EN/Y2016/V03/I01/46

References 43

[1]	DingY，ChoiME.Autophagy in diabetic nephropathy [J]. J Endocrinol, 2015，224(1)：R15-R30.
[2]	ZarzynskaJM .The importance of autophagy regulation in breast cancer development and treatment[J]．Biomed Res Int，2014，2014：710345.
[3]	NagataE,SaiardiA,TsukamotoH，et al. Inositol hexakisphosphate kinases promote autophagy[J]. Int J Biochem Cell Biol, 2010 , 42(12)：2065-2071.
[4]	MaycotteP，ThorburnA．Targeting autophagy in breast cancer[J]. World J Clin Oncol, 2014 , 5(3)：224-240.
[5]	ChenS,RehmanSK,ZhangW，et al. Autophagy is a therapeutic target in anticancer drug resistance[J]. Biochim Biophys Acta，2010，1806(2)：220-229.
[6]	HouG,YangS,ZhouY, et al. Targeted inhibition of mTOR signaling improves sensitivity of esophageal squamous cell carcinoma cells to cisplatin[J]. J Immunol Res，2014，2014：845763.
[7]	NishikawaT,TakaokaM,OharaT, et al. Antiproliferative effect of a novel mTOR inhibitor temsirolimus contributes to the prolonged survival of orthotopic esophageal cancer-bearing mice[J]. Cancer Biol Ther，2013，14(3)：230-236.
[8]	OngCA,ShannonNB,Ross-InnesCS, et al. Amplification of TRIM44: pairing a prognostic target with potential therapeutic strategy[J]. JNCI J Natl Cancer Inst，2014，106(5) pii: dju050.
[9]	PaplomataE,O'ReganR. The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers[J]. Ther Adv Med Oncol，2014，6(4)：154-166.
[10]	ZhongY,WangQJ,LiX，et al. Distinct regulation of autophagic activity by Atg14L and Rubicon associated with Beclin1- phosphatidylinositol 3-kinase complex[J]. Nat Cell Biol, 2009，11(4): 468-476.
[11]	KoukourakisMI,GiatromanolakiA，SivridisE, et al. Beclin1 over- and underexpression in colorectal cancer: distinct patterns relate to prognosis and tumour hypoxia[J]. Br J Cancer, 2010，103(8)：1209-1214.
[12]	RoeslyHB,KhanMR,ChenHD，et al. The decreased expression of Beclin-1 correlates with progression to esophageal adenocarcinoma: the role of deoxycholic acid[J]. Am J Physiol Gastrointest Liver Physiol，2012，302(8)：G864-G872.
[13]	WangTT,CaoQH,ChenMY, et al. Beclin1 deficiency correlated with lymph node metastasis, predicts a distinct outcome in intrahepatic and extrahepatic cholangiocarcinoma[J]. PLoS One, 2013，8(11)：e80317.
[14]	GuoGF,JiangWQ, et al. Autophagy-related proteins Beclin-1 and LC3 predict cetuximab efficacy in advanced colorectal cancer[J]. World J Gastroenterol, 2011，17(43)：4779-4786.
[15]	ChenZ,LiY,ZhangC, et al. Downregulation of Beclin1 and impairment of autophagy in a small population of colorectal cancer[J]. Dig Dis Sci, 2013，58(10)：2887-2894.
[16]	GengQR,XuDZ,HeLJ, et al. Beclin-1 expression is a significant predictor of survival in patients with lymph node-positive gastric cancer[J]. PLoS One, 2012, 7(9)：e45968.
[17]	SakuraiT,OkumuraH,MatsumotoM，et al. The expression of LC-3 is related to tumor suppression through angiogenesis in esophageal cancer[J]. Med Oncol，2013，30(4)：701.
[18]	HaoCL,LiY,YangHX，et al. High level of microtubule-associated protein light chain 3 predicts poor prognosis in resectable esophageal squamous cell carcinoma[J]. Int J Clin Exp Pathol，2014，7(7)：4213-4221.
[19]	WangBS,YangY,YangH, et al. PKCι counteracts oxidative stress by regulating Hsc70 in an esophageal cancer cell line[J]. Cell Stress Chaperones, 2013，18(3)：359-366.
[20]	LiouGY,StorzP. Reactive oxygen species in cancer[J]. Free Radic Res，2010，44(5)：479-496.
[21]	BrownNS,BicknellR. Hypoxia and oxidative stress in breast cancer. Oxidative stress: its effects on the growth, metastatic potential and response to therapy of breast cancer[J]. Breast Cancer Res，2001，3(5)：323-327.
[22]	TongM,ChanKW,BaoJY, et al. Rab25 is a tumor suppressor gene with antiangiogenic and anti-invasive activities in esophageal squamous cell carcinoma[J]. Cancer Res, 2012, 72(22)：6024-6035.
[23]	XuX,GuanX,TaoH, et al. An association study on genetic polymorphisms of Rab37 gene with the risk of esophageal squamous cell carcinoma in a Chinese Han population[J]. Int J Med Sci，2013，10(3)：235-242.
[24]	ShiGZ,YuanY,JiangGJ, et al. PRAF3 induces apoptosis and inhibits migration and invasion in human esophageal squamous cell carcinoma[J]. BMC Cancer，2012，12：97.
[25]	GarciaCJ,Castro-CombsJ,DiasA，et al. Insulin/insulin-like growth factor-1 pathway in Barrett’s carcinogenesis[J]．Clin Transl Gastroenterol，2013，4：e40.
[26]	WangY,DingQ,YenCJ, et al. MC: The crosstalk of mTOR/S6K1 and Hedgehog pathways[J]. Cancer Cell，2012, 21(3)：374-387.
[27]	KimmelmanAC. The dynamic nature of autophagy in cancer[J]. Genes Dev，2011，25(19)：1999-2010.
[28]	LuJ,SunD,GaoS, et al. Cyclovirobuxine D induces autophagy-associated cell death via the Akt/mTOR pathway in MCF-7 human breast cancer cells[J]. J Pharmacol Sci，2014，125(1)：74-82.
[29]	KenificCM,ThorburnA,DebnathJ. Autophagy and metastasis: another double-edged sword[J]. Curr Opin Cell Biol，2010，22(2)：241-245.
[30]	ChoiKS. Autophagy and cancer[J]. Exp Mol Med，2012，44(2)：109-120.
[31]	ChenN,KarantzaV. Autophagy as a therapeutic target in cancer[J]. Cancer Biol Ther, 2011, 11：157-68.
[32]	ZhaoZ,OhS,LiD, et al. A dual role for UVRAG in maintaining chromosomal stability independent ofautophagy[J]. Dev Cell，2012，22(5)：1001-1016.
[33]	HaoQ,ChoWC. Battle against cancer: an everlasting saga of p53[J]. Int J Mol Sci, 2014，15(12)：22109-22127.
[34]	RingerL,SirajuddinP,TricoliL, et al. The induction of the p53 tumor suppressor protein bridges the apoptoticand autophagic signaling pathways to regulate cell death in prostate cancercells[J]. Oncotarget, 2014，5(21)：10678-10691.
[35]	RabinowitzJD,WhiteE. Autophagy and metabolism[J]. Science，2010，330: 1344-1348.
[36]	PortaC,PaglinoC,MoscaA. Targeting PI3K/Akt/mTOR Signaling in Cancer[J]. Front Oncol.，2014, 4: 64.
[37]	MorranDC,WuJ,JamiesonNB, et al. Targeting mTOR dependency in pancreatic cancer[J]. Gut. 2014. 63(9): 1481-1489.
[38]	O'DonovanTR,O'SullivanGC,McKennaSL. Induction of autophagy by drug-resistant esophageal cancer cells promotes their survival and recovery following treatment with chemotherapeutics[J]. Autophagy，2011，7(5)：509-524.
[39]	ChengC,VerstovsekS,CancerLett. The BH3-mimetic GX15-070 induces autophagy, potentiates the cytotoxicity of carboplatin and 5-fluorouracil in esophageal carcinoma cells[J]. Cancer Lett，2010，293(2)：167-174.
[40]	DuffyA,LeJ,SausvilleE, et al. Autophagy modulation: a target for cancer treatment development[J]. Cancer Chemother Pharmacol, 2015，75(3)：439-447.
[41]	YardleyDA,NoguchiS,PritchardKI, et al. Everolimus plus exemestane in postmenopausal patients with HR(＋) breast cancer: BOLERO-2 final progression-free survival analysis[J]. Adv Ther, 2013，30(10)：870-884.
[42]	OceanAJ,ChristosP,SparanoJA, et al. Phase Ⅱ trial of bortezomib alone or in combination with irinotecan in patients with adenocarcinoma of the gastroesophageal junction or stomach[J]. Invest New Drugs, 2014，32(3)：542-548.
[43]	MaHB,DiZL,WenJ, et al. Prospective, open, multicentre Phase Ⅰ/Ⅱ trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and cisplatin for esophageal carcinoma[J]. Jpn J Clin Oncol, 2015，45(2)：169-175.

Please choose a citation manager

Content to export